6533b830fe1ef96bd1296627
RESEARCH PRODUCT
Effect of antiviral treatment and host susceptibility on positive selection in hepatitis C virus (HCV).
Alma BrachoEnrique OrtegaInmaculada García-roblesManuela Torres-puenteAndrés MoyaNuria Jiménez-hernándezJosé A. CastroVicente SentandreuJuan A. Del OlmoFernando González-candelasFernando Carnicersubject
AdultMaleCancer ResearchCombination therapyHepatitis C virusMolecular Sequence DataDiseaseHepacivirusBiologyViral Nonstructural Proteinsmedicine.disease_causeAntiviral Agentschemistry.chemical_compoundViral Envelope ProteinsInterferonVirologyRibavirinmedicineHumansAmino Acid SequenceSelection GeneticNS5AAgedHost (biology)Positive selectionRibavirinSequence Analysis DNAMiddle AgedHepatitis CInfectious DiseasesTreatment OutcomechemistryAmino Acid SubstitutionImmunologyRNA ViralFemaleInterferonsmedicine.drugdescription
Abstract We have conducted a large sequence study of the E1–E2 and NS5A regions of the HCV, subtypes 1a and b, both in patients previously treated with interferon, and untreated patients, who later responded, or not, to a combination therapy based on interferon plus ribavirin. We have examined the role played by the number of positively selected sites on disease progression and its relationship with several variables such as patients’ age, sex and their risk of acquiring the disease. We have detected three groups of patients that respond or not to combination therapy: responders of intermediate age, older non-responders and young non-responders, they possess an increasing average number of positively selected sites in the E1–E2 region, respectively. We conclude that the host's genetic factors play an important role in whether the disease is contained or becomes chronic.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2007-05-07 | Virus research |